

**4basebio PLC**

("4basebio" or the "Company")

**Employee Long Term Incentive Plan and Issue of Equity**

**Cambridge, UK, 22 July 2025** - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that, pursuant to the Employees Benefit Trust (the "EBT") operated by Fiduchi Trustees (UK) Limited, the EBT has been awarded 29,125 ordinary shares of EUR 1.00 each in the Company (the "EBT Shares") at £9.85 per ordinary share, being the closing mid-market price on 7 July 2025.

As announced on 18 July 2024, the EBT was established as part of the employee long-term incentive plan and is a discretionary trust for the benefit of employees of the Company.

The Directors approved the issue of the EBT shares on 18 July 2025. The next allocation is expected to take place during July 2026 and the market will be updated at that time.

Following the settlement of the award of the EBT Shares, the EBT will hold a total of 53,643 shares in the Company, equivalent to 0.19 per cent. of the Company's enlarged issued share capital.

**Issue of Equity and Admission Total Voting Rights**

The EBT Shares will be fully paid and will rank *pari passu* in all respects with the existing ordinary shares of the Company, including, without limitation, the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Application has been made for the EBT Shares to be admitted to trading on AIM (the "Admission"). Admission and settlement of the EBT Shares is expected to take place at 8.00 a.m. on 23 July 2025.

Following Admission, the total number of ordinary shares in issue will be 15,538,518. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares with voting rights will be 15,538,518. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

**For further enquiries, please contact:**

**4basebio PLC** +44 (0)1223 967 943

Dr. Heikki Lanckriet, CEO  
Nominated Adviser +44 (0)20 7213 0880

**Caim Financial Advisers LLP**

Jo Tuner / Sandy Jamieson / Ed Downes  
Joint Broker +44 (0)20 7653 4000

**RBC Capital Markets**

Kathryn Deegan / Matthew Coakes  
Joint Broker +44 (0)20 7220 0500

**Cavendish Capital Markets Limited**

Geoff Nash / Nigel Birks

**Notes to Editors****About 4basebio**

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

**Forward-looking statements**

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.